The DOI matches its Crossref record; 57 of the 57 references it cites were found in a registry or an index.
Passive immunization targeting pathological phospho‐tau protein in a mouse model reduces functional decline and clears tau aggregates from the brain
Open accessAbstract
J. Neurochem. (2011) 118, 658–667. Targeting hyperphosphorylated tau by immunotherapy is emerging as a promising approach to treat tauopathies such as Alzheimer’s disease and frontotemporal dementia. We have previously reported that active tau immunization clears tau aggregates from the brain and attenuates or prevents functional impairments in two different tangle mouse models. Here, we assessed the efficacy of passive immunization with the PHF1 antibody, which targets a phospho‐epitope within one of our active immunogens. Homozygous female tangle mice (JNPL3, 2–3 months) were injected intraperitoneally once per week with PHF1 or pooled mouse IgG (250 μg/125 μL; n = 10 per group) for a total of 13 injections. Their behavior was assessed at 5–6 months of age and brain tissue was subsequently harvested for analyses of treatment efficacy. The treated mice performed better than controls on the traverse beam task (p < 0.03), and had 58% less tau pathology in the dentate gyrus of the hippocampus (p = 0.02). As assessed by western blots, the antibody therapy reduced the levels of insoluble pathological tau by 14–27% (PHF1, p < 0.05; PHF1/total tau, p < 0.0001) and 34–45% (CP13 or CP13/total tau, p < 0.05). Levels of soluble tau and sarkosyl soluble tau were unchanged, compared with controls, as well as total tau levels in all the fractions. Plasma levels of PHF1 correlated inversely with tau pathology in the brainstem (p < 0.01), with a strong trend in the motor cortex (p < 0.06) as well as with insoluble total tau levels (p < 0.02), indicating that higher dose of antibodies may have a greater therapeutic effect. Significant correlation was also observed between performance on the traverse beam task and PHF1 immunoreactivity in the dentate gyrus (p < 0.05) as well as with insoluble PHF1/total tau ratio on western blots (p < 0.04). These results show that passive immunization with tau antibodies can decrease tau pathology and functional impairments in the JNPL3 model. Future studies will determine the feasibility of this approach with other monoclonals and in different tangle models in which thorough cognitive assessment can be performed.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“The first reports of successful active and passive immunization against tau in a tauopathy mouse model, using a phospho-tau peptide comprising the pSer396/404 epitope or the PHF1 antibody against this epitope185–188, came from our group.”
From Tau-targeting therapies for Alzheimer disease (2018) · cites this paper as [186]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Immunization with amyloid-β attenuates Alzheimer-disease-like pathology in the PDAPP mouse
Schenk, D., Barbour, R., Dunn, W., Gordon, G., Grajeda, H., Guido, T., Hu, K., Huang, J., Johnson-Wood, K., Khan, K., et al. (1999) · Nature · doi:10.1038/22124 · Cited by 3,160
Bard, F., Cannon, C., Barbour, R., Burke, R.-L., Games, D., Grajeda, H., Guido, T., Hu, K., Huang, J., Johnson-Wood, K., et al. (2000) · Nature Medicine · doi:10.1038/78682 · Cited by 2,012
Transmission and spreading of tauopathy in transgenic mouse brain
Clavaguera, F., Bolmont, T., Crowther, R. A., Abramowski, D., Frank, S., Probst, A., Fraser, G., Stalder, A. K., Beibel, M., Staufenbiel, M., et al. (2009) · Nature Cell Biology · doi:10.1038/ncb1901 · Cited by 1,803
Aβ peptide vaccination prevents memory loss in an animal model of Alzheimer's disease
Morgan, D., Diamond, D. M., Gottschall, P. E., Ugen, K. E., Dickey, C. A., Hardy, J., Duff, K., Jantzen, P. T., DiCarlo, G., Wilcock, D. M., et al. (2000) · Nature · doi:10.1038/35050116 · Cited by 1,506
Aβ peptide immunization reduces behavioural impairment and plaques in a model of Alzheimer's disease
Janus, C., Pearson, J., McLaurin, J., Mathews, P. M., Jiang, Y., Schmidt, S. D., Chishti, M. A., Horne, P., Heslin, D., French, J., et al. (2000) · Nature · doi:10.1038/35050110 · Cited by 1,431
Holmes, C., Boche, D., Wilkinson, D., Yadegarfar, G., Hopkins, V., Bayer, A., Jones, R. W., Bullock, R., Love, S., Neal, J. W., et al. (2008) · The Lancet · doi:10.1016/s0140-6736(08)61075-2 · Cited by 1,416 · cited 1×
“However, recent findings from this trial indicate that plaque clearance did not halt or slow the progression of dementia, emphasizing the need for alternative targets (Holmes et al. 2008).”
BackgroundNeuropathology of human Alzheimer disease after immunization with amyloid-β peptide: a case report
Nicoll, J. A. R., Wilkinson, D., Holmes, C., Steart, P., Markham, H., & Weller, R. O. (2003) · Nature Medicine · doi:10.1038/nm840 · Cited by 1,397
Lewis, J., McGowan, E., Rockwood, J., Melrose, H., Nacharaju, P., Van Slegtenhorst, M., Gwinn-Hardy, K., Murphy, M. P., Baker, M., Yu, X., et al. (2000) · Nature Genetics · doi:10.1038/78078 · Cited by 1,371
Self-citationSubacute meningoencephalitis in a subset of patients with AD after Aβ42 immunization
Orgogozo, J.-M., Gilman, S., Dartigues, J.-F., Laurent, B., Puel, M., Kirby, L. C., Jouanny, P., Dubois, B., Eisner, L., Flitman, S., et al. (2003) · Neurology · doi:10.1212/01.wnl.0000073623.84147.a8 · Cited by 1,356
Clinical effects of Aβ immunization (AN1792) in patients with AD in an interrupted trial
Gilman, S., Koller, M., Black, R. S., Jenkins, L., Griffith, S. G., Fox, N. C., Eisner, L., Kirby, L., Rovira, M. B., Forette, F., et al. (2005) · Neurology · doi:10.1212/01.wnl.0000159740.16984.3c · Cited by 1,329
Cited by
Sorted by citations
Items 101–200 of 304
Gerson, J. E., Castillo‐Carranza, D. L., & Kayed, R. (2014) · ACS Chemical Neuroscience · doi:10.1021/cn500143n · Cited by 75
Krishnamurthy, P., Deng, Y., & Sigurdsson, E. M. (2011) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2011.00059 · Cited by 73
Self-citationLebouvier, T., Pasquier, F., & Buée, L. (2017) · Current Opinion in Neurology · doi:10.1097/wco.0000000000000502 · Cited by 77
Tau Immunotherapies for Alzheimer’s Disease and Related Tauopathies: Progress and Potential Pitfalls
Sigurdsson, E. M. (2018) · Journal of Alzheimer s Disease · doi:10.3233/jad-189010 · Cited by 67
Self-citationRepeated immunization of mice with phosphorylated-tau peptides causes neuroinflammation
Rozenstein-Tsalkovich, L., Grigoriadis, N., Lourbopoulos, A., Nousiopoulou, E., Kassis, I., Abramsky, O., Karussis, D., & Rosenmann, H. (2013) · Experimental Neurology · doi:10.1016/j.expneurol.2013.07.006 · Cited by 66
Alzheimer’s disease: biological aspects, therapeutic perspectives and diagnostic tools
Carlo, M. D., Giacomazza, D., & Biagio, P. L. S. (2012) · Journal of Physics Condensed Matter · doi:10.1088/0953-8984/24/24/244102 · Cited by 67
Antibody-DerivedIn VivoImaging of Tau Pathology
Krishnaswamy, S., Lin, Y., Rajamohamedsait, W. J., Rajamohamedsait, H. B., Krishnamurthy, P., & Sigurdsson, E. M. (2014) · Journal of Neuroscience · doi:10.1523/jneurosci.2755-14.2014 · Cited by 62
Self-citationTau-targeting therapy in Alzheimer’s disease: Critical advances and future opportunities
Guo, Y., Li, S., Zeng, L.-H., & Tan, J. (2022) · Ageing and Neurodegenerative Diseases · doi:10.20517/and.2022.16 · Cited by 61
Tau neurotoxicity and rescue in animal models of human Tauopathies
Krüger, L., & Mandelkow, E. (2015) · Current Opinion in Neurobiology · doi:10.1016/j.conb.2015.09.004 · Cited by 63
Daulatzai, M. A. (2016) · Europe PMC (PubMed Central) · Cited by 60
RetractedClavaguera, F., Grueninger, F., & Tolnay, M. (2013) · Neuropharmacology · doi:10.1016/j.neuropharm.2013.08.037 · Cited by 68
Niewidok, B., Igaev, M., Sündermann, F., Janning, D., Bakota, L., & Brandt, R. (2016) · Molecular Biology of the Cell · doi:10.1091/mbc.e16-06-0402 · Cited by 62
Liu, S., Breitbart, A., Sun, Y., Mehta, P. D., Boutajangout, A., Scholtzova, H., & Wisniewski, T. (2014) · Journal of Neurochemistry · doi:10.1111/jnc.12484 · Cited by 60
Self-citationBehind the curtain of tauopathy: a show of multiple players orchestrating tau toxicity
Huang, Y., Wu, Z., & Zhou, B. (2015) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-015-2042-8 · Cited by 58
Sensitive quantitative assays for tau and phospho-tau in transgenic mouse models
Acker, C. M., Forest, S. K., Zinkowski, R., Davies, P., & d’Abramo, C. (2012) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2012.05.010 · Cited by 59
Self-citationp-Tau immunotherapy reduces soluble and insoluble tau in aged 3xTg-AD mice
Walls, K. C., Ager, R. R., Vasilevko, V., Cheng, D., Medeiros, R., & LaFerla, F. M. (2014) · Neuroscience Letters · doi:10.1016/j.neulet.2014.05.047 · Cited by 62
Developing therapeutic vaccines against Alzheimer’s disease
Wısnıewskı, T., & Drummond, E. (2015) · Expert Review of Vaccines · doi:10.1586/14760584.2016.1121815 · Cited by 60
AAV-mediated expression of anti-tau scFvs decreases tau accumulation in a mouse model of tauopathy
Ising, C., Gallardo, G., Leyns, C. E. G., Wong, C. H., Jiang, H., Stewart, F., Koscal, L. J., Roh, J., Robinson, G. O., Remolina Serrano, J., et al. (2017) · Journal of Experimental Medicine · doi:10.1084/jem.20162125 · Cited by 57
Progress in Target Drug Molecules for Alzheimer's Disease
Xie, J., Liang, R., Wang, Y., Huang, J., Cao, X., & Niu, B. (2019) · Current Topics in Medicinal Chemistry · doi:10.2174/1568026619666191203113745 · Cited by 57
Tau Filament Self-Assembly and Structure: Tau as a Therapeutic Target
Oakley, S. S., Maina, M. B., Marshall, K. E., Al‐Hilaly, Y. K., Harrington, C., Wischik, C. M., & Serpell, L. C. (2020) · Frontiers in Neurology · doi:10.3389/fneur.2020.590754 · Cited by 59
Singh, A., Allen, D., Fracassi, A., Tumurbaatar, B., Natarajan, C., Scaduto, P., Woltjer, R., Kayed, R., Limon, A., Krishnan, B., et al. (2020) · Journal of Alzheimer's Disease · doi:10.3233/jad-200716 · Cited by 56
Sigurdsson, E. M. (2016) · Neurodegenerative Diseases · doi:10.1159/000440842 · Cited by 56
Self-citationBeyond amyloid: Getting real about nonamyloid targets in Alzheimer's disease
Herrup, K., Carrillo, M. C., Schenk, D., Cacace, A. M., DeSanti, S., Fremeau, R. T., Bhat, R. V., Glicksman, M. A., May, P. C., Swerdlow, R. H., et al. (2013) · Alzheimer s & Dementia · doi:10.1016/j.jalz.2013.01.017 · Cited by 55
Vitale, F., Giliberto, L., Ruiz, S., Steslow, K., Marambaud, P., & d’Abramo, C. (2018) · Acta Neuropathologica Communications · doi:10.1186/s40478-018-0585-2 · Cited by 59
Agadjanyan, M. G., Zagorski, K., Petrushina, I., Davtyan, H., Kazarian, K., Antonenko, M., Davis, J. L., Bon, C., Blurton-Jones, M. M., Cribbs, D. H., et al. (2017) · Molecular Neurodegeneration · doi:10.1186/s13024-017-0172-1 · Cited by 56
The evolving landscape of Alzheimer’s disease therapy: From Aβ to tau
Courade, J., Zetterberg, H., Höglinger, G. U., & Dewachter, I. (2025) · Cell · doi:10.1016/j.cell.2025.11.033 · Cited by 57
Strang, K. H., Goodwin, M. S., Riffe, C. J., Moore, B. D., Chakrabarty, P., Levites, Y., Golde, T. E., & Giasson, B. I. (2017) · Acta Neuropathologica Communications · doi:10.1186/s40478-017-0458-0 · Cited by 53
Prion‐like propagation as a pathogenic principle in frontotemporal dementia
Hock, E., & Polymenidou, M. (2016) · Journal of Neurochemistry · doi:10.1111/jnc.13668 · Cited by 58
Highly specific and selective anti‐pS396‐tau antibody C10.2 targets seeding‐competent tau
Rosenqvist, N., Asuni, A. A., Andersson, C. R., Christensen, S., Daechsel, J. C. A., Egebjerg, J., Falsig, J., Helboe, L., Jul, P., Kartberg, F., et al. (2018) · Alzheimer s & Dementia Translational Research & Clinical Interventions · doi:10.1016/j.trci.2018.09.005 · Cited by 52
Self-citationAntibody Therapeutics Targeting Aβ and TauPreprint
Gallardo, G., & Holtzman, D. M. (2017) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a024331 · Cited by 55
Tau-directed approaches for the treatment of Alzheimer’s disease: focus on leuco-methylthioninium
Seripa, D., Solfrizzi, V., Imbimbo, B. P., Daniele, A., Santamato, A., Lozupone, M., Zuliani, G., Greco, A., Logroscino, G., & Panza, F. (2016) · Expert Review of Neurotherapeutics · doi:10.1586/14737175.2016.1140039 · Cited by 50
Natural Antibodies as Rheostats for Susceptibility to Chronic Diseases in the Aged
Rothstein, T. L. (2016) · Frontiers in Immunology · doi:10.3389/fimmu.2016.00127 · Cited by 50
Rajamohamedsait, H., Rasool, S., Rajamohamedsait, W., Lin, Y., & Sigurdsson, E. M. (2017) · Scientific Reports · doi:10.1038/s41598-017-17313-1 · Cited by 49
Self-citationSchroeder, S. K., Joly‐Amado, A., Gordon, M. N., & Morgan, D. (2015) · Journal of Neuroimmune Pharmacology · doi:10.1007/s11481-015-9637-6 · Cited by 51
Intravenous immunoglobulin and Alzheimer’s disease: what now?
Loeffler, D. A. (2013) · Journal of Neuroinflammation · doi:10.1186/1742-2094-10-70 · Cited by 52
Passive Immunization in JNPL3 Transgenic Mice Using an Array of Phospho-Tau Specific Antibodies
d’Abramo, C., Acker, C. M., Jimenez, H. T., & Davies, P. (2015) · PLoS ONE · doi:10.1371/journal.pone.0135774 · Cited by 49
Self-citationQß Virus-like particle-based vaccine induces robust immunity and protects against tauopathy
Maphis, N. M., Peabody, J., Crossey, E., Jiang, S., Ahmad, F. A. J., Álvarez, M. J., Mansoor, S. K., Yaney, A., Yang, Y., Sillerud, L. O., et al. (2019) · npj Vaccines · doi:10.1038/s41541-019-0118-4 · Cited by 48
NPT088 reduces both amyloid‐β and tau pathologies in transgenic mice
Levenson, J. M., Schroeter, S., Carroll, J. C., Cullen, V., Asp, E., Proschitsky, M., Chung, C. H. ‐., Gilead, S., Nadeem, M., Dodiya, H. B., et al. (2016) · Alzheimer's & Dementia: Translational Research & Clinical Interventions · doi:10.1016/j.trci.2016.06.004 · Cited by 47
Immunity and Alzheimer's disease: immunological perspectives on the development of novel therapies
Liu, Y.-H., Zeng, F., Wang, Y., Zhou, H., Giunta, B. N., Tan, J., & Wang, Y. (2013) · Drug Discovery Today · doi:10.1016/j.drudis.2013.07.020 · Cited by 48
Gaikwad, S., Puangmalai, N., Sonawane, M., Montalbano, M., Price, R., Iyer, M. S., Ray, A., Moreno, S., & Kayed, R. (2024) · Science Translational Medicine · doi:10.1126/scitranslmed.adj5958 · Cited by 46
A Generic Method for Design of Oligomer-Specific Antibodies
Brännström, K., Lindhagen‐Persson, M., Gharibyan, A. L., Iakovleva, I., Vestling, M., Sellin, M. E., Brännström, T., Morozova‐Roche, L. A., Forsgren, L., & Olofsson, A. (2014) · PLoS ONE · doi:10.1371/journal.pone.0090857 · Cited by 45
Gibbons, G. S., Kim, S., Wu, Q., Riddle, D. M., Leight, S. N., Changolkar, L. N., Xu, H. W., Meymand, E. S., O’Reilly, M., Zhang, B., et al. (2020) · Molecular Neurodegeneration · doi:10.1186/s13024-020-00404-5 · Cited by 45
Adenosine receptor signalling in Alzheimer’s disease
Trinh, P. N. H., Baltos, J., Hellyer, S. D., May, L. T., & Gregory, K. J. (2022) · Purinergic Signalling · doi:10.1007/s11302-022-09883-1 · Cited by 43
A Review of Treatment Options for Progressive Supranuclear Palsy
Stamelou, M., & Höglinger, G. U. (2016) · CNS Drugs · doi:10.1007/s40263-016-0347-2 · Cited by 43
Goodwin, M. S., Sinyavskaya, O., Burg, F., O’Neal, V., Ceballos‐Diaz, C., Cruz, P. E., Lewis, J. M., Giasson, B. I., Davies, P., Golde, T. E., et al. (2020) · Molecular Therapy · doi:10.1016/j.ymthe.2020.10.007 · Cited by 46
Self-citationFurther understanding of tau phosphorylation: implications for therapy
Medina, M., & Avila, J. (2015) · Expert Review of Neurotherapeutics · doi:10.1586/14737175.2015.1000864 · Cited by 41
Progressive supranuclear palsy
Giagkou, N., Höglinger, G. U., & Stamelou, M. (2019) · International review of neurobiology · doi:10.1016/bs.irn.2019.10.013 · Cited by 44
Corsetti, V., Borreca, A., Latina, V., Giacovazzo, G., Pignataro, A., Krashia, P., Natale, F., Cocco, S., Rinaudo, M., Malerba, F., et al. (2020) · Brain Communications · doi:10.1093/braincomms/fcaa039 · Cited by 42
Annadurai, N., Sanctis, J. B. D., Hajdúch, M., & Das, V. (2021) · Experimental Neurology · doi:10.1016/j.expneurol.2021.113756 · Cited by 41
Selenica, M.-L. B., Davtyan, H., Housley, S. B., Blair, L. J., Gillies, A., Nordhues, B. A., Zhang, B., Liu, J., Gestwicki, J. E., Lee, D. C., et al. (2014) · Journal of Neuroinflammation · doi:10.1186/s12974-014-0152-0 · Cited by 40
Drug pipeline in neurodegeneration based on transgenic mice models of Alzheimer's disease
Li, C., Ebrahimi, A., & Schluesener, H. J. (2012) · Ageing Research Reviews · doi:10.1016/j.arr.2012.09.002 · Cited by 44
Emerging Diagnostic and Therapeutic Strategies for Tauopathies
Coughlin, D. G., & Irwin, D. J. (2017) · Current Neurology and Neuroscience Reports · doi:10.1007/s11910-017-0779-1 · Cited by 42
Anti-amyloid-beta to tau-based immunization: developments in immunotherapy for Alzheimer's disease
Lambracht‐Washington, D., & Rosenberg, R. N. (2013) · ImmunoTargets and Therapy · doi:10.2147/itt.s31428 · Cited by 39
Prion-Like Propagation of Protein Aggregation and Related Therapeutic Strategies
Kaufman, S. K., & Diamond, M. I. (2013) · Neurotherapeutics · doi:10.1007/s13311-013-0196-3 · Cited by 40
Marciniuk, K., Taschuk, R., & Napper, S. (2013) · Clinical and Developmental Immunology · doi:10.1155/2013/473706 · Cited by 39
Congdon, E. E., Jiang, Y., & Sigurdsson, E. M. (2021) · Seminars in Cell and Developmental Biology · doi:10.1016/j.semcdb.2021.12.002 · Cited by 38
Self-citationTau and Alzheimer's disease: Past, present and future
Iqbal, K. (2024) · Cytoskeleton · doi:10.1002/cm.21822 · Cited by 35
Carroll, T., Guha, S. K., Nehrke, K. W., & Johnson, G. V. W. (2021) · Biology · doi:10.3390/biology10101047 · Cited by 39
Amyloid beta peptide immunotherapy in Alzheimer disease
Delrieu, J., Ousset, P., Voisin, T., & Vellas, B. J. (2014) · Revue Neurologique · doi:10.1016/j.neurol.2014.10.003 · Cited by 35
Gu, J., & Sigurdsson, E. M. (2011) · Journal of Molecular Neuroscience · doi:10.1007/s12031-011-9576-5 · Cited by 36
Self-citationShamir, D. B., Rosenqvist, N., Rasool, S., Pedersen, J. T., & Sigurdsson, E. M. (2016) · Alzheimer s & Dementia · doi:10.1016/j.jalz.2016.01.013 · Cited by 34
Self-citationCurrent Strategies for the Delivery of Therapeutic Proteins and Enzymes to Treat Brain Disorders
Duskey, J. T., Belletti, D., Pederzoli, F., Vandelli, M. A., Forni, F., Ruozi, B., & Tosi, G. (2017) · International review of neurobiology · doi:10.1016/bs.irn.2017.08.006 · Cited by 34
Lin, Y., Rajamohamedsait, H. B., Sandusky‐Beltran, L. A., Gamallo‐Lana, B., Mar, A. C., & Sigurdsson, E. M. (2020) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2019.00377 · Cited by 34
Self-citationSaidi, L.-J., Polydoro, M., Kay, K. R., Sanchez, L., Mandelkow, E., Hyman, B. T., & Spires‐Jones, T. L. (2015) · Journal of Alzheimer s Disease · doi:10.3233/jad-142094 · Cited by 34
Progressive Supranuclear Palsy and Corticobasal Degeneration
Coughlin, D. G., Dickson, D. W., Josephs, K. A., & Litvan, I. (2021) · Advances in experimental medicine and biology · doi:10.1007/978-3-030-51140-1_11 · Cited by 33
Prion-like Mechanisms in Alzheimer's Disease
Yin, R., Tan, L., Jiang, T., & Yu, J. (2014) · Current Alzheimer Research · doi:10.2174/156720501108140910121425 · Cited by 33
Tau immunization: a cautionary tale?
Mably, A. J., Kanmert, D., Donald, J. M. M., Liu, W., Caldarone, B. J., Lemere, C. A., O’Nuallain, B., Kosik, K. S., & Walsh, D. M. (2014) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2014.11.022 · Cited by 32
Kabir, M. T., Uddin, M. S., Mathew, B., Das, P. K., Perveen, A., & Ashraf, G. M. (2020) · Current Topics in Medicinal Chemistry · doi:10.2174/1568026620666200422105156 · Cited by 32
Inappropriately chelated iron in the cerebrospinal fluid of amyotrophic lateral sclerosis patients
Ignjatović, A., Stević, Z., Lavrnić, D., Nikolić‐Kokić, A., Blagojević, D. P., Spasić, M. B., & Spasojević, I. (2012) · Amyotrophic Lateral Sclerosis · doi:10.3109/17482968.2012.665929 · Cited by 30
Intravenous immunoglobulin products contain specific antibodies to recombinant human tau protein
Smith, L. M., Coffey, M. P., Klaver, A. C., & Loeffler, D. A. (2013) · International Immunopharmacology · doi:10.1016/j.intimp.2013.04.034 · Cited by 30
Chukwu, J. E., Pedersen, J. T., Pedersen, L. Ø., Volbracht, C., Sigurdsson, E. M., & Kong, X. (2018) · Scientific Reports · doi:10.1038/s41598-018-24276-4 · Cited by 32
Self-citationJoly‐Amado, A., Davtyan, H., Serraneau, K. S., Jules, P., Zitnyar, A., Pressman, E., Zagorski, K., Antonyan, T., Hovakimyan, A., Paek, H., et al. (2019) · Neurobiology of Disease · doi:10.1016/j.nbd.2019.104636 · Cited by 30
Shared pathophysiology: Understanding stroke and Alzheimer’s disease
Sriram, S., Mehkri, Y., Quintin, S. S., & Lucke-Wold, B. P. (2022) · Clinical Neurology and Neurosurgery · doi:10.1016/j.clineuro.2022.107306 · Cited by 29
Dynamic assessment of tau immunotherapies in the brains of live animals by two-photon imaging
Wu, Q., Lin, Y., Gu, J., & Sigurdsson, E. M. (2018) · EBioMedicine · doi:10.1016/j.ebiom.2018.08.041 · Cited by 31
Self-citationSpencer, B. J., Brüschweiler, S., Sealey‐Cardona, M., Rockenstein, E. M., Adame, A., Florio, J. B., Mante, M., Trinh, I., Rissman, R. A., Konrat, R., et al. (2018) · Acta Neuropathologica · doi:10.1007/s00401-018-1869-0 · Cited by 30
Muza, P. M., Bachmeier, C. J., Mouzon, B., Algamal, M., Rafi, N. G., Lungmus, C., Abdullah, L. I., Evans, J. E., Ferguson, S., MULLAN, M. J., et al. (2019) · Neuroscience · doi:10.1016/j.neuroscience.2019.01.049 · Cited by 28
Inflammation, Autoimmunity and Neurodegenerative Diseases, Therapeutics and Beyond
Garmendia, J. V., Sanctis, C. V. D., Das, V., Annadurai, N., Hajdúch, M., & Sanctis, J. B. D. (2023) · Current Neuropharmacology · doi:10.2174/1570159x22666231017141636 · Cited by 27
Sigurdsson, E. M. (2024) · Journal of Alzheimer s Disease · doi:10.3233/jad-231238 · Cited by 28
Self-citationFroestl, W., Pfeifer, A., & Muhs, A. (2013) · Journal of Alzheimer s Disease · doi:10.3233/jad-121729 · Cited by 27
Sidoryk‐Wȩgrzynowicz, M., Adamiak, K., & Strużyńska, L. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms252212448 · Cited by 26
Subramanian, S., Savanur, G., & Madhavadas, S. (2016) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2016.12.101 · Cited by 25
Daulatzai, M. A. (2016) · Neurotoxicity Research · doi:10.1007/s12640-016-9643-3 · Cited by 27
Passive immunization against phosphorylated tau improves features of Huntington's disease pathology
Alpaugh, M., Masnata, M., de Rus Jacquet, A., Lepinay, E., Denis, H. L., Saint-Pierre, M., Davies, P., Planel, E., & Cicchetti, F. (2022) · Molecular Therapy · doi:10.1016/j.ymthe.2022.01.020 · Cited by 25
Self-citationNg, P. Y., Chang, I. S., Koh, R. Y., & Chye, S. M. (2020) · Metabolic Brain Disease · doi:10.1007/s11011-020-00591-6 · Cited by 25
Amyloid-β in Alzheimer’s disease – front and centre after all?
Weglinski, C., & Jeans, A. F. (2022) · Neuronal Signaling · doi:10.1042/ns20220086 · Cited by 24
“Tau immunotherapy: Hopes and hindrances”
Shahpasand, K., Shamloo, A. S., Nabavi, S. M., Lu, K. P., & Zhou, X. Z. (2017) · Human Vaccines & Immunotherapeutics · doi:10.1080/21645515.2017.1393594 · Cited by 25
Albayram, Ö., MacIver, B., Mathai, J., Verstegen, A. M. J., Baxley, S., Qiu, C., Bell, C. A., Caldarone, B. J., Zhou, X. Z., Lu, K. P., et al. (2019) · Scientific Reports · doi:10.1038/s41598-019-45234-8 · Cited by 26
Bajracharya, R., Cruz, E., Götz, J., & Nisbet, R. M. (2022) · Journal of Controlled Release · doi:10.1016/j.jconrel.2022.07.026 · Cited by 27
Sigurdsson, E. M. (2013) · Neurodegenerative Diseases · doi:10.1159/000354491 · Cited by 23
Self-citationGhosal, K., Fan, Q., Dawson, H. N., & Pimplikar, S. W. (2016) · PLoS ONE · doi:10.1371/journal.pone.0159435 · Cited by 24
Neuronally expressed anti-tau scFv prevents tauopathy-induced phenotypes in Drosophila models
Krishnaswamy, S., Huang, H.-W., Marchal, I. S., Ryoo, H. D., & Sigurdsson, E. M. (2020) · Neurobiology of Disease · doi:10.1016/j.nbd.2020.104770 · Cited by 24
Self-citationAlzheimer’s Disease: Dawn of a New Era?
Amirrad, F., Bousoik, E., Shamloo, K., Al-Shiyab, H., Nguyen, V.-H. V., & Montazeri Aliabadi, H. (2017) · Journal of Pharmacy & Pharmaceutical Sciences · doi:10.18433/j3vs8p · Cited by 21
“Passive immunization with specific monoclonal antibodies directed against phosphorylated tau is being studied and are in various stages of pre-clinical testing (101, 102).”
BackgroundLi, D., & Cho, Y. K. (2019) · Journal of Neurochemistry · doi:10.1111/jnc.14830 · Cited by 23
Pharmacotherapy for Frontotemporal Dementia
Khoury, R., Liu, Y., Sheheryar, Q., & Grossberg, G. T. (2021) · CNS Drugs · doi:10.1007/s40263-021-00813-0 · Cited by 22
Messenger RNA-encoded antibody approach for targeting extracellular and intracellular tau
Wongsodirdjo, P., Caruso, A. C., Yong, A., Lester, M. A., Vella, L. J., Hung, Y. H., & Nisbet, R. M. (2024) · Brain Communications · doi:10.1093/braincomms/fcae100 · Cited by 20
Harnessing the Immune System for Treatment and Detection of Tau Pathology
Congdon, E. E., Krishnaswamy, S., & Sigurdsson, E. M. (2014) · Journal of Alzheimer s Disease · doi:10.3233/jad-132435 · Cited by 20
Self-citationBasurto‐Islas, G., Diaz, M. C., Zavala-Ocampo, L. M., Martínez‐Herrera, M., & López-Camacho, P. Y. (2025) · Archiv der Pharmazie · doi:10.1002/ardp.202400721 · Cited by 20
Clinical Trials: Past, Current, and Future for Atypical Parkinsonian Syndromes
Boxer, A. L., & Tsai, R. M. (2014) · Seminars in Neurology · doi:10.1055/s-0034-1381739 · Cited by 19
Sontag, J., Schuhmacher, D., Taleski, G., Jordan, A., Khan, S. Z., Hoffman, A., Gomez, R. J., Mazalouskas, M. D., Hanks, S. K., Spiller, B. W., et al. (2022) · Journal of Biological Chemistry · doi:10.1016/j.jbc.2022.102248 · Cited by 19
Bittar, A., Al-Lahham, R., Bhatt, N., Moore, K., Montalbano, M., Jerez, C., Fung, L., McAllen, S., Ellsworth, A., & Kayed, R. (2022) · Journal of Alzheimer's Disease · doi:10.3233/jad-220518 · Cited by 18
Metadata
- Authors
- Boutajangout, A., Ingadottir, J., Davies, P., & Sigurdsson, E. M.
- Affiliations
- New York University (US)
- University of Iceland (IS)
- Albert Einstein College of Medicine (US)
- Corresponding author
- Sigurdsson, Einar M.
- Venue
- Journal of Neurochemistry
- Publisher
- Wiley
- Published
- 2011-07
- Volume
- 118
- Issue
- 4
- Pages
- 658-667
- ISSN
- 0022-3042 (ISSN-L)
- 1471-4159
- PMC
- PMC3366469
- OpenAlex
- W1538003756
- Cited by
- 306
- References
- 57
- Citations by year
- 2026: 6 · 2025: 11 · 2024: 13 · 2023: 10 · 2022: 14 · 2021: 15 · 2020: 22 · 2019: 19 · 2018: 23 · 2017: 25 · 2016: 27 · 2015: 30 · 2014: 35 · 2013: 33 · 2012: 17
- FWCI
- 20.06
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Journal of Neurochemistry (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- Funders
- Alzheimer's Association (AG032611)
- National Institutes of Health
- National Institute on Aging (R01AG020197, AG032611, R37AG022102, AG022102, AG 020197, R01AG022102, R01AG032611)
- National Institute of Mental Health (R37MH038623, MH38623, R01MH038623)
- Topics
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Life Sciences › Neuroscience › Neurology › Neuroinflammation and Neurodegeneration Mechanisms
- Keywords
- passive immunization, hyperphosphorylated tau, tau immunotherapy, tauopathy, Alzheimer's disease, frontotemporal dementia, tau aggregates, motor function, dentate gyrus, neurodegenerative disease treatment
- MeSH terms
- Animals, Antibodies, Antibodies, Monoclonal, Astrocytes, Brain, Brain Chemistry, Brain Stem, Data Interpretation, Statistical, Enzyme-Linked Immunosorbent Assay, Postural Balance, Female, Gliosis, Image Processing, Computer-Assisted, Immunization, Passive, Immunohistochemistry, Motor Activity, Motor Cortex, Phosphorylation, Blotting, Western, tau Proteins, Dentate Gyrus, Antibodies, Blocking, Neurodegenerative Diseases, Tauopathies, Mice
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
